Current oncologyPub Date : 2025-01-17DOI: 10.3390/curroncol32010048
Anna Spreafico, Eric Winquist, Cheryl Ho, Brian O'Sullivan, Nathaniel Bouganim, Neil Chua, Sarah Doucette, Lillian L Siu, Desiree Hao
{"title":"A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma.","authors":"Anna Spreafico, Eric Winquist, Cheryl Ho, Brian O'Sullivan, Nathaniel Bouganim, Neil Chua, Sarah Doucette, Lillian L Siu, Desiree Hao","doi":"10.3390/curroncol32010048","DOIUrl":"10.3390/curroncol32010048","url":null,"abstract":"<p><p>Although the majority of patients with nasopharyngeal carcinoma (NPC) present with early-stage or locoregional disease that can be treated with definitive radiotherapy, approximately 20% of patients experience disease recurrence, and 15% present with metastatic disease that is not amenable to curative therapy. Management of patients with recurrent or metastatic (r/m) NPC who are not candidates for local salvage therapy is challenging in Canada, as there is uncertainty in extrapolating evidence that is largely generated from Southeast China to non-endemic regions such as Canada. Currently, treatment options in Canada are limited to chemotherapy regimens that can only achieve short-term response and prolongation of survival. The addition of anti-PD-1 monoclonal antibodies to chemotherapy has been shown to extend progression-free survival in recurrent r/m NPC compared to chemotherapy alone; however, approval of PD-1 inhibitors in Canada has lagged behind other jurisdictions where NPC is non-endemic. This paper reviews the current systemic treatment landscape for r/m NPC in Canada, highlights unmet treatment needs for patients who are not candidates for curative therapy, and discusses the challenges and opportunities that lie in emerging therapies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-17DOI: 10.3390/curroncol32010044
Alexander Bray, Vaibhav Sahai
{"title":"IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies.","authors":"Alexander Bray, Vaibhav Sahai","doi":"10.3390/curroncol32010044","DOIUrl":"10.3390/curroncol32010044","url":null,"abstract":"<p><p>Mutations in isocitrate dehydrogenase (IDH) genes are among the most frequently encountered molecular alterations in cholangiocarcinoma (CCA). These neomorphic point mutations endow mutant IDH (mIDH) with the ability to generate an R-enantiomer of 2-hydroxyglutarate (R2HG), a metabolite that drives malignant transformation through aberrant epigenetic signaling. As a result, pharmacologic inhibition of mIDH has become an attractive therapeutic strategy in CCAs harboring this mutation. One such inhibitor, ivosidenib, has already undergone clinical validation and received FDA approval in this disease, but there is still much work to be done to improve outcomes in mIDH CCA patients. In this publication we will review the pathogenesis and treatment of mIDH CCA with special emphasis on novel agents and combinations currently under investigation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-17DOI: 10.3390/curroncol32010045
Véronique Turcotte, Laurence Guillaumie, Martine Lemay, Anne Dionne, Julie Lemieux, Angéline Labbé, Carolyn Gotay, Line Guénette, Sophie Lauzier
{"title":"Perspectives of Women with Breast Cancer and Healthcare Providers Participating in an Adherence-Enhancing Program for Adjuvant Endocrine Therapy: A Qualitative Study.","authors":"Véronique Turcotte, Laurence Guillaumie, Martine Lemay, Anne Dionne, Julie Lemieux, Angéline Labbé, Carolyn Gotay, Line Guénette, Sophie Lauzier","doi":"10.3390/curroncol32010045","DOIUrl":"10.3390/curroncol32010045","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant endocrine therapy (AET) is prescribed for 5-10 years to women with hormone-sensitive breast cancer to prevent recurrence. However, a significant proportion of women do not adhere to AET. We developed SOIE, a one-year program designed to enhance the AET experience and adherence. SOIE was pilot-tested in a mixed-methods randomized controlled trial. This report presents the experience of women and healthcare providers (HCPs) with SOIE.</p><p><strong>Methods: </strong>A descriptive qualitative study using semi-structured interviews and thematic analysis was conducted with 20 women and 7 HCPs who participated in the program.</p><p><strong>Results: </strong>Most women and HCPs reported high satisfaction with the program. Women felt it addressed their need for information and strategies to manage side effects. They felt supported and developed a more positive attitude toward AET, which contributed to their intention to pursue AET. They perceived that the program helped them navigate the AET experience and reduced their stress or fear regarding AET. HCPs corroborated these benefits.</p><p><strong>Conclusions: </strong>Findings suggest that SOIE can enhance the experience and motivation to pursue the AET treatment by meeting important needs for information, side-effects management, and psycho-emotional support. Programs like SOIE can have benefits beyond adherence by improving patients' well-being during this crucial long-term treatment.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-17DOI: 10.3390/curroncol32010047
Anna C Nuijens, Arlene L Oei, Nicolaas A P Franken, Coen R N Rasch, Lukas J A Stalpers
{"title":"Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.","authors":"Anna C Nuijens, Arlene L Oei, Nicolaas A P Franken, Coen R N Rasch, Lukas J A Stalpers","doi":"10.3390/curroncol32010047","DOIUrl":"10.3390/curroncol32010047","url":null,"abstract":"<p><p>Normal tissue reactions vary significantly among patients receiving the same radiation treatment regimen, reflecting the multifactorial etiology of late radiation toxicity. Predicting late radiation toxicity is crucial, as it aids in the initial decision-making process regarding the treatment modalities. For patients undergoing radiotherapy, anticipating late toxicity allows for planning adjustments to optimize individualized care. Various dosimetric parameters have been shown to influence the incidence of late toxicity, and the literature available on this topic is extensive. This narrative review examines patient-related determinants of late toxicity following external beam radiotherapy for pelvic tumors, with a focus on prostate and cervical cancer patients. In Part I, we address various methods for quantifying radiation toxicity, providing context for interpreting toxicity data. Part II examines the current insights into the clinical risk factors for late toxicity. While certain factors-such as previous abdominal surgery, smoking behavior, and severe acute toxicity-have consistently been reported, most of the others show inconsistent associations. In Part III, we explore the influence of genetic factors and discuss promising predictive assays. Single-nucleotide polymorphisms (SNPs) likely elevate the risk in specific combinations. Advances in artificial intelligence now allow for the identification of SNP patterns from large datasets, supporting the development of polygenic risk scores. These innovations hold promise for improving personalized treatment strategies and reducing the burden of late toxicity in cancer survivors.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-17DOI: 10.3390/curroncol32010046
Andrea Messori, Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, Alessandro Inno, Vera Damuzzo
{"title":"Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials.","authors":"Andrea Messori, Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, Alessandro Inno, Vera Damuzzo","doi":"10.3390/curroncol32010046","DOIUrl":"10.3390/curroncol32010046","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs), either alone or in combination with platinum-based chemotherapy, are effective in the first-line treatment of metastatic, non-oncogene-addicted, non-small cell lung cancer (NSCLC). However, when NSCLC patients progress, the efficacy of available treatment options is limited.</p><p><strong>Methods: </strong>We undertook a meta-analysis that compared combination regimens with the current standard of care. Only randomized controlled trials (RCTs) were included (endpoint, overall survival [OS]). Our analysis used an artificial intelligence software program that reconstructs individual patient data from Kaplan-Meier curves. Hazard ratio (HR) with 95% confidence interval (CI) was the main parameter. Heterogeneity was based on Wald's test and likelihood ratio test.</p><p><strong>Results: </strong>Five RCTs were included, whose experimental arms included five different combinations. In our analysis, these combination regimes showed no OS benefit compared to chemotherapy (HR = 1.066, 95%CI, 0.9311 to 1.221; <i>p</i> = 0.35). Among the five control arms, cross-trial heterogeneity was remarkably low (likelihood ratio test = 3.76 on 4 df, <i>p</i> = 0.40; Wald test = 3.83 on 4 df, <i>p</i> = 0.40.</p><p><strong>Discussion: </strong>In conclusion, five new second-line combination treatments for patients with NSCLC were not found to determine any benefit in terms of OS in comparison with the current standard of care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-16DOI: 10.3390/curroncol32010043
Dorah Ursula Ramathuba, Neo Jacqueline Ramutumbu
{"title":"Psychosocial Distress and the Quality of Life of Cancer Patients in Rural Hospitals in Limpopo Province: A Qualitative Study.","authors":"Dorah Ursula Ramathuba, Neo Jacqueline Ramutumbu","doi":"10.3390/curroncol32010043","DOIUrl":"10.3390/curroncol32010043","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis and treatment of cancer are associated with substantial physical, psychological, and social morbidity for most patients. Distress can be seen as an unpleasant experience of an emotional, psychological, social, or spiritual nature that interferes with the ability to cope with cancer treatment.</p><p><strong>Purpose: </strong>The aim was to understand patients' experiences of distress in their context and to analyze and interpret the findings.</p><p><strong>Method: </strong>An explorative, descriptive qualitative study was conducted among cancer patients receiving treatment and care at rural hospitals in Limpopo. A face-to-face individual interview was conducted to determine the participants' cancer-related experiences and quality of life. Thematic analysis was conducted following Tesch's method, and the themes developed were subjected to a triangulation process to ensure the validity and rigor of the findings.</p><p><strong>Findings: </strong>The participants revealed experiences of symptomatic distress resulting in biopsychosocial distress such as pain, fatigue, emotional distress related to prognosis and uncertainty about the future, psychosocial distress related to a lack or absence of support, financial instability, and poor self-esteem.</p><p><strong>Conclusions: </strong>Cancer patients face many challenges during their treatment journey. Participants were drained by anxiety and uncertainty of the cancer trajectory and required psychosocial support. The oncology team must provide supportive preventive measures for side effects management and culture-sensitive psychotherapy at an early stage to improve their quality of life.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.","authors":"Hironari Tamiya, Kazumi Nishino, Yuji Kato, Reina Nakahashi-Kato, Yurika Kosuga-Tsujimoto, Shota Kinoshita, Rie Suzuki, Makiyo Watanabe, Toru Wakamatsu, Shigeki Kakunaga, Satoshi Takenaka","doi":"10.3390/curroncol32010042","DOIUrl":"10.3390/curroncol32010042","url":null,"abstract":"<p><strong>Background: </strong>Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival.</p><p><strong>Methods: </strong>A total of 539 cancer patients were retrospectively analyzed to identify significant independent factors in post-bone metastasis survival.</p><p><strong>Results: </strong>Among the overall population, patients with the following cancers had a median survival longer than 24 months: thyroid, 97.2 months; breast, 51.5 months; prostate, 47.2 months; and kidney, 38.8 months. In contrast, median post-bone metastasis survival was significantly shorter in gastrointestinal (GI) (6.5 months), head and neck (6.3 months), and urinary tract (3.4 months) cancers. In non-small cell lung cancer (NSCLC), the log-rank test demonstrated that the epidermal growth factor receptor (EGFR) mutation was a significant factor for post-bone metastasis survival: EGFR mutation (-) <i>n</i> = 67, median post-bone metastasis survival 11.5 months (95% CI: 6.0-15.2); EGFR mutation (+) <i>n</i> = 39, median post-bone metastasis survival 28.8 months (95% CI: 18.1-35.7) (<i>p</i> < 0.05). Intriguingly, treatment with BMA was a significant positive prognostic factor: BMA (-) <i>n</i> = 203, median post-bone metastasis survival 7.8 months (95% CI: 5.8-12.5); BMA (+) <i>n</i> = 336, median post-bone metastasis survival 21.9 months (95% CI: 16.1-26.4) (<i>p</i> < 0.001). Moreover, the Cox proportional hazards model showed that this was particularly evident in cancer types with poor prognosis such as GI cancer (hazard ratio [HR]: 0.62, 95% CI: 0.40-0.95; <i>p</i> < 0.05) and NSCLC without the epidermal growth factor receptor (EGFR) mutation (HR: 0.56, 95% CI: 0.34-0.91; <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Treatment with BMA is recommended not only for the prevention and/or treatment of SRE, but also may have a positive impact on post-bone metastasis survival, particularly in cancers with typically poor post-bone metastasis survival such as GI cancer and NSCLC without the EGFR mutation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-14DOI: 10.3390/curroncol32010041
Manuel De Jesus Encarnacion Ramirez, Gervith Reyes Soto, Carlos Castillo Rangel
{"title":"A Journey into the Complexity of Temporo-Insular Gliomas: Case Report and Literature Review.","authors":"Manuel De Jesus Encarnacion Ramirez, Gervith Reyes Soto, Carlos Castillo Rangel","doi":"10.3390/curroncol32010041","DOIUrl":"10.3390/curroncol32010041","url":null,"abstract":"<p><strong>Introduction: </strong>Temporo-insular gliomas, rare brain tumors originating from glial cells, comprise about 30% of brain tumors and vary in aggressiveness from grade I to IV. Despite advancements in neuroimaging and surgical techniques, their management remains complex due to their location near critical cognitive areas. Techniques like awake craniotomy have improved outcomes, but tumor heterogeneity and proximity to vital structures pose challenges. Radiotherapy and chemotherapy offer benefits post-surgery, though issues like resistance and side effects persist. This article discusses a case report and literature review to deepen understanding of temporo-insular gliomas, focusing on advanced diagnostic and treatment approaches.</p><p><strong>Materials and methods: </strong>A systematic review was conducted using PubMed, Embase, and Google Scholar, covering studies from 2019 to July 2024. Keywords included 'brain tumor', 'neurosurgery', and 'treatment'. Articles on glioma diagnosis, management, and outcomes were selected, excluding non-English studies, irrelevant reports, non-glioma research, and inaccessible texts.</p><p><strong>Results: </strong>From 156 studies, 11 met inclusion criteria, highlighting advanced diagnostics, surgical strategies, and adjunct therapies for temporo-insular gliomas (TIGs). Gross total resection (GTR) was achieved in 39% of cases. Awake craniotomy enhanced functional outcomes, while temozolomide and radiotherapy improved survival. Challenges included ischemic complications and treatment resistance. Two patient cases underscored the complexity of TIG management and the importance of individualized approaches, achieving satisfactory resection with minimal deficits.</p><p><strong>Conclusions: </strong>Temporo-insular gliomas (TIGs) necessitate a multidisciplinary strategy that integrates advanced imaging, meticulous surgical methods, and cutting-edge adjuvant therapies. Despite progress with techniques like awake craniotomy and the use of temozolomide improving patient outcomes, significant challenges persist in maintaining functional integrity and addressing treatment resistance. Ongoing research into targeted therapies, immunotherapies, and innovative technologies remains critical to advancing patient care and improving long-term prognosis.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-14DOI: 10.3390/curroncol32010040
Matteo Renzulli, Emanuela Giampalma
{"title":"Hepatocellular Carcinoma: Imaging Advances in 2024 with a Focus on Magnetic Resonance Imaging.","authors":"Matteo Renzulli, Emanuela Giampalma","doi":"10.3390/curroncol32010040","DOIUrl":"10.3390/curroncol32010040","url":null,"abstract":"<p><p>The EASL diagnostic algorithm for hepatocellular carcinoma, currently in use, dates back to 2018. While awaiting its update, numerous advancements have emerged in the field of hepatocellular carcinoma imaging. These innovations impact every step of the diagnostic algorithm, from surveillance protocols to diagnostic processes, encompassing aspects preceding a patient's inclusion in surveillance programs as well as the potential applications of imaging after the hepatocellular carcinoma diagnosis. Notably, these diagnostic advancements are particularly evident in the domain of magnetic resonance imaging. For example, the sensitivity of ultrasound in diagnosing very early-stage and early-stage hepatocellular carcinoma during the surveillance phase is very low (less than 50%) and a potential improvement in this sensitivity value could be achieved by using abbreviated protocols in magnetic resonance imaging. The aim of this review is to explore the 2024 updates in magnetic resonance imaging for hepatocellular carcinoma, with a focus on its role in surveillance, nodular size assessment, post-diagnosis imaging applications, and its potential role before the initiation of surveillance.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2025-01-13DOI: 10.3390/curroncol32010037
Dorela-Codruta Lazureanu, Amelia Burlea, Robert Barna, Daniela Cipu, Mihaela Pasca Fenesan, Ioan Icma, Marioara Cornianu
{"title":"Insights into the Multidisciplinary Approach for Metastatic Acinic Cell Lung Carcinoma: The Pathologist's Role in Romania Today.","authors":"Dorela-Codruta Lazureanu, Amelia Burlea, Robert Barna, Daniela Cipu, Mihaela Pasca Fenesan, Ioan Icma, Marioara Cornianu","doi":"10.3390/curroncol32010037","DOIUrl":"10.3390/curroncol32010037","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Acinic cell carcinoma (ACC) is a rare lung neoplasm that can affect both children and adults as a parenchymal or endobronchial mass. It is histologically similar to this kind of tumor described in salivary glands, but with a different immunophenotype. In general, it poses a reduced degree of malignancy, with indolent growth and a favorable prognosis, with exceptionally rare cases associated with recurring disease or lymph node metastases. <b>Methods</b>: When clinicians are facing puzzling symptomatology in their patients, the main role of the multidisciplinary team in their review of oncological cases is to recommend imagistic-guided biopsies. Tissues samples were routinely processed, stained with hematoxylin-eosin (HE) and periodic acid-Schiff (PAS), and submitted to complementary immunohistochemistry tests. <b>Results</b>: Histopathological reports were consistent for lung ACC with regional lymph node involvement and remote metastases. Oncological therapies followed. <b>Conclusions</b>: Postponements of the presentation to the doctor at the onset of symptoms, as well as a lack of periodic health control for people insured by national health insurance companies, often lead to medical, human and financial complications that are difficult to manage. The pathologist involved in the discussion of oncological cases brings his expertise in solving cases, certifying the evolution of tumors considered less aggressive, such as in the case of lung ACCs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}